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Abstract
Myeloid-derived cells play important modulatory and effector roles in multiple sclerosis (MS) and 
its animal model, experimental autoimmune encephalomyelitis (EAE). Myeloid-derived 
suppressor cells (MDSCs) are immature myeloid cells, composed of monocytic (MO) and 
polymorphonuclear (PMN) fractions, which can suppress T cell activities in EAE. Their role in 
MS remains poorly characterized. We found decreased numbers of circulating MDSCs, driven by 
lower frequencies of the MO-MDSCs, and higher MDSC expression of microRNA miR-223 in 
MS versus healthy subjects. To gain mechanistic insights, we interrogated the EAE model. 
MiR-223 knock out (miR-223−/−) mice developed less severe EAE with increased MDSC numbers 
in the spleen and spinal cord compared to littermate controls. MiR-223−/− MO-MDSCs suppressed 
T cell proliferation and cytokine production in vitro and EAE in vivo more than wild-type MO-
MDSCs. They also displayed an increased expression of critical mediators of MDSC suppressive 
function, Arginase-1(Arg1), and the signal transducer and activator of transcription 3 (Stat3), 
which herein, we demonstrate being an miR-223 target gene. Consistently, MDSCs from MS 
patients displayed decreased STAT3 and ARG1 expression compared with healthy controls, 
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suggesting that circulating MDSCs in MS are not only reduced in numbers but also less 
suppressive. These results support a critical role for miR-223 in modulating MDSC biology in 
EAE and in MS and suggest potential novel therapeutic applications.
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Introduction
Multiple sclerosis (MS) is a complex disease of unknown etiology involving central nervous 
system (CNS) inflammation, demyelination, and axonal damage. Most MS patients (about 
85 %) initially show a relapsing-remitting disease course (RRMS), but around half of these 
later develop secondary progressive MS. MS is thought to be an autoimmune disease 
targeting CNS myelin, in part based on the success in using its prime animal model 
experimental autoimmune encephalomyelitis (EAE) to develop several currently approved 
MS therapies [41]. In EAE, and very likely in MS, myelin-specific CD4+ T cells, T helper 
(Th)1 and Th17, are generated in peripheral lymphoid organs, where they are activated and 
then circulate in the blood stream before gaining access to the CNS [10]. Once inside the 
CNS compartment, myelin-specific T cells are reactivated after encountering the specific 
antigen and trigger the recruitment of a large number of monocyte/macrophages and 
neutrophils from the circulating blood, which results in CNS inflammation [43]. In recent 
years, it has become clear that a heterogeneous population of myeloid cells, called myeloid-
derived suppressor cells (MDSCs), including immature granulocytes, monocytes, and 
dendritic cells, plays a very important role in shaping T cell responses [11]. There are two 
different types of MDSCs, as identified in both human and mice: polymorphonuclear 
MDSCs (PMN-MDSCs) morphologically and phenotypically similar to neutrophils and 
monocytic (MO-MDSCs) which are similar to monocytes [4]. MDSCs can suppress T cell 
activities and are reported to modulate the clinical course and pathology of EAE [48, 49]. 
The mechanisms by which these cells are sustained during relapsing and chronic 
neuroinflammation are poorly understood. Likewise, the immunomodulatory role of MDSCs 
in MS has not been well addressed up to now. A single report has shown that PMN-MDSCs 
from MS patients potently suppress the activation and proliferation of autologous T cell in 
vitro [18]. Immunosuppression by MDSCs involves multiple mechanisms, including 
depletion of L-arginine (a key nutritional factor needed for T cell proliferation) via 
arginase-1 (ARG1) and increased production of nitric oxide (NO) and reactive oxygen 
species (ROS) by inducible NO synthase (iNOS) and the NADPH oxidase (NOX), 
respectively [36, 37]. The signal transducer and activator of transcription 3 (STAT3) is 
another very important factor that drives the expansion of MDSCs in cancer [11] and their 
suppressive function by the regulation of ARG1 activity [45]. The possible role of these 
pathways in MDSCs has not been investigated in the context of CNS autoimmunity yet.
MicroRNAs (miRNAs) are a class of small, non-coding RNAs that regulate gene expression 
post-transcriptionally, either by targeting mRNA degradation or by inhibiting protein 
translation. The importance of miRNAs in biological processes is evidenced by their high 
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conservation across species and the fact that they target almost a third of human genes [1, 
28]. MiRNAs are implicated in the pathogenesis of several diseases, including MS [14, 21], 
and they represent potential therapeutic targets that can readily be manipulated [2]. In prior 
studies, we discovered that cell-free miR-223 is decreased in serum of MS patients 
compared to healthy controls [9]. In contrast, miR-223 expression has been found to be 
increased in peripheral blood cells (whole blood and regulatory T cells) from MS patients 
compared to healthy subjects, [6, 23] as well as in active MS lesions compared to normal 
CNS areas in controls subjects [22]. MiR-223 is highly expressed in the myeloid 
compartment and acts as an important modulator of myeloid cell development and functions 
[20]. MiR-223 negatively regulates myeloid progenitor proliferation, and lack of miR-223 
was associated with MDSC accumulation in the presence of an infection or a growing tumor 
through the inverse modulation of its target gene myocyte enhancer factor 2C (Mef2c) [20, 
30, 35]. MiR-223 expression is not confined to the MDSCs. In humans, miR-223 is 
expressed in granulocyte subsets [8, 12], and its expression decreases during monocytes/
macrophage differentiation [29].
In this study, we show that RRMS patients displayed lower numbers of suppressive MDSCs, 
more specifically MO-MDSCs, in the peripheral blood which was associated with 
significantly higher expression of miR-223 in MDSCs in MS patients compared to healthy 
controls. In the EAE model, miR-223 knockout (miR-223−/−) mice developed a less severe 
disease characterized by the accumulation of MDSCs and lower production of IL-17A and 
GM-CSF by CNS-isolated T cells compared to control mice. MO-MDSCs isolated from 
miR-223−/− mice were more suppressive toward T cell proliferation and cytokine production 
in vitro and in EAE in vivo compared to MO-MDSCs from WT cells. Mechanistically, 
greater suppressive function of miR-223−/− MO-MDSCs was associated with higher 
expression of Arg1 and Stat3, which herein, we demonstrate being a miR-223 target gene. 
Consistently, MDSCs from MS patients had lower expression of STAT3 and ARG1. Our 
results support the contention that miR-223 can regulate the number and function of MO-
MDSCs in EAE and MS, which in turn modulate T cell responses that favor the amelioration 
of CNS inflammation.
Materials and methods
Subjects
This project was approved by the Institutional Review Board (IRB) at Washington 
University in St. Louis. All subjects provided informed consent. This population was 
recruited at the John L. Trotter MS Center, Washington University School of Medicine, 
Department of Neurology, St. Louis (Missouri, USA). The characteristics of patients and 
healthy controls are summarized in Supplementary Table 1a, b. All the MS patients met the 
2010 McDonald’s criteria for MS diagnosis [40]. Of the 34 MS patients [24 untreated and 
10 treated with glatiramer acetate (GA)] included in flow cytometric analyses and of the 11 
subjects with MS used for cell sorting, four in the first group and two in the second were 
experiencing a relapse at the time of analysis. For gene expression studies in circulating 
MDSCs, healthy control subjects were matched for age and gender to the MS group. 
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Untreated RRMS subjects had not taken disease-modifying therapies or corticosteroids for at 
least 3 months before and at the time of blood collection.
Flow cytometry analyses
Staining of human MO- and PMN-MDSCs was performed using anti-human antibodies to 
CD33 (Biolegend, 303408), CD14 (eBioscience, 25-0149-42), CD15 (Biolegend, 301904), 
and HLA-DR (Beckman Coulter, 2017-03-21) starting from 100 μl of heparinized whole 
human blood which was incubated with the antibodies for 30 min at RT. Subsequently, 
samples were fixed and lysed with Step Fix/Lyse Solution (Affimetrix, eBioscience) at room 
temperature (RT) for 30 min. To calculate absolute cell numbers, 100 μl of 123count eBeads 
Solution (Affimetrix, eBioscience) were added to each sample before flow cytometric 
analysis according to manufacture instructions. Samples were analyzed on a Gallios Flow 
Cytometer (Beckman Coulter). Staining of murine tissues used anti-mouse antibodies to 
CD11b (BD Pharmigen 553311), Ly-6G (eBioscience, 15-5931-82), Ly-6C (eBioscience, 
47-5932-82), CD4 (Biolegend, 100443), CD3 (Biolegend, 100216), CD45.1 (Biolegend, 
110716), CD40 (BD Pharmigen, 553790), CD86 (Biolegend, 105012), and CD274 (PD-L1) 
(BD Pharmigen, 55809). After isolation, cells were labeled with the various fluorochrome-
conjugated antibodies and the survival marker Zombie Dye for 25 min at 4 °C, washed, and 
analyzed on a the Gallios Flow Cytometer. Data analysis was performed by gating on 
Zombie Dye negative cells. Staining for intracellular cytokines encompassed anti-mouse 
antibodies to IL-17A (Biolegend, 506908), IL-10 (Biolegend, 505028), GM-CSF 
(Biolegend, 505406), IFN-γ (Biolegend, 505810), and TNF-α (eBioscience 11-7321-81). 
Isolated cells were incubated in 96 well plates for 5–6 h with 50 ng/ml of PMA and 750 
ng/ml of Ionomicin (both from Sigma) and Monensin (eBioscience) at 37 °C. Surface 
staining was performed for 25 min at 4 °C. Subsequently, cells were fixed in 2 % PFA for 10 
min at RT and then permeabilized in Saponin Buffer for another 10 min at RT. Cytokine 
staining was performed in permeabilization buffer for 25 min at 4 °C. Samples were run on 
the Gallios Flow Cytometer, and data were analyzed using FlowJo (Tree Star Inc.).
Human MDSC sorting
For human MDSC sorting, PBMCs were isolated by Ficoll-density centrifugation and then 
processed for cell sorting using anti-human CD33 and HLA-DR antibodies on an FACS 
ARIA (BD Bioscience). CD33b+HLA-DRneg MDSCs were collected and frozen for RNA 
extraction.
Animals
Animal protocols were approved by the Washington University Animal Studies Committee. 
MiR-223−/− and littermate-derived wild-type (WT) mice (C57Bl/6 background) were 
obtained from Dr. Todd Fehniger and bred at Washington University. The miR-223 gene is 
located on the X chromosome, and mice were bred as miR-223−/y or littermate miR-223+/y 
(termed WT throughout the manuscript) males with heterozygous females. MiR-223−/− and 
WT mice deriving from these breeding pairs were used in all experiments. C57BL/6 mice 
transgenic for a TCR with specificity for the peptide MOG35–55 (TCRMOG mice, also 
referred to as 2D2 mice; The Jackson Laboratory) were screened by flow cytometric analysis 
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of peripheral blood cells using a specific antibody to Vβ11 (BD Biosciences) [3]. Mice were 
6–9 weeks of age at the initiation of the studies.
EAE induction and histology
Mice were immunized with MOG35–55 (Sigma Genosys) to induce EAE as previously done 
[39]. In adoptive transfer experiments, MOG35–55-specific Th1 cells were generated as 
described [13]. Briefly, donor mice were immunized with MOG35–55 peptide. Spleens were 
removed 14 days post-immunization, and CD4+ T cells were purified and maintained in 
culture in the presence of irradiated splenocytes, IL-12 and IL-2 (eBioscience). Cells were 
restimulated weekly, and after the sixth stimulation MOG-specific T cells were harvested, 
washed, and transferred intravenously at 10 × 106 cells/mouse to induce EAE. In some 
active EAE experiments, miR-223−/− or WT MO-MDSCs obtained in vitro (see below for 
methodological details) were injected (2 × 106 cells) intravenously on day 5 post-
immunization. The control group was injected with PBS. Timing of MDSCs transfer in EAE 
was decided based on prior reports in the literature [49]. For both active and adoptive 
transfer EAE, mice were evaluated clinically in a blinded fashion using a scale from 0 to 5 
as previously described [39].
Histological and immunofluorescence microscopy analyses
CNS tissues were dissected from mice perfused with buffered 4 % paraformaldehyde, then 
embedded in paraffin. Slides were stained with hematoxylin & eosin (H&E) [39] and with 
solochrome cyanine to stain myelin as previously described [24]. For the latter, sections 
were stained with Eriochrome Cyanine R (Sigma), washed, differentiated in 10 % iron (III) 
chloride (Sigma), and counter-stained with Van Gieson’s stain. The quantification of 
inflammation and demyelination was performed in a blinded fashion as previously reported 
[38]. Distributions of injured axons and demyelinated axons were identified with double-
staining experiments using antibodies to nonphosphorylated neuro-filaments (SMI32 at 
1:200; Sternberger Monoclonals) and myelin basic protein (MBP; at 1:200; Zymed 
Laboratories Inc.), respectively. MBP and SMI32 staining were analyzed as the percentage 
area of positive staining (number of positive pixels/1 mm2) within the area of interest. For 
immunofluorescence assays on in vitro derived MO-MDSCs, the following primary 
antibodies were used: anti-mouse Gr1 (1:200; Abcam) and ARG1 (1:200; Abcam). Sections 
were blocked with 5 % horse serum and 0.1 % triton-X in PBS for 1 h, and primary 
antibodies were applied overnight at 4 °C degree. Next, sections were incubated with 
fluorescently labeled secondary antibodies for 1 h at RT (Invitrogen) and mounted on a slide 
using a Fluoroshield Mounting Medium with DAPI (Abcam). The total number of 
ARG1+Gr1+ cells was divided by the total number of Gr1+ cells to calculate the percentage 
of double positive cells. Images were acquired using a Nikon Eclipse 90i fluorescent and 
bright field microscope and analyzed for quantification with the Metamorph 7.7 software.
Mouse MDSC isolation
Murine MDSCs were generated in vitro from the bone marrow (BM) of miR-223−/− and WT 
mice. BM was flushed, and red blood cells were lysed with red blood cells lysis buffer 
(Sigma). To obtain MDSCs, the remaining cells were plated with medium supplemented 
with GM-CSF (40 ng/ml) and IL-6 (40 ng/ml) and cultured at 37 °C in 5 % CO2-humidified 
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atmosphere for 4 days. PMN- and MO-MDSCs were purified from the mixed population of 
BM-derived cells by immunomagnetic separation using biotinylated anti-Ly6G and anti-Gr1 
antibodies and streptavidin-conjugated MicroBeads with MiniMACS columns according to 
manufacturer’s protocol (Miltenyi Biotec). In vitro functional assays were done with PMN-
MDSCs and MO-MDSC subsets. Cell purity was confirmed by flow cytometric analysis 
using anti-CD11b and Gr-1 antibodies (purity >95 %), and viability was assessed by Trypan 
blue dye exclusion.
T cell suppression assays
For Ag-specific proliferation, MOG-specific CD4+ T cells were purified from 2D2 mice by 
CD4-positive selection (L34T, Milteny Kit) with a final purity ≥95 %. CD4+ T cells (105 
cells/well) were cultured at different ratios with PMN- or MO-MDSCs (8:1, 4:1, and 2:1; 
CD4+ T cells: MDSCs) in the presence of 20 μg/ml MOG35–55 and irradiated splenocytes 
from C57BL/6 mice (1:1 for T cells: irradiated splenocytes). For CFSE-based proliferation 
assay, CD4+ T cells were incubated with 1 mM CFSE for 15 min at 37 °C, quenched in 
culture medium for 30 min, and washed before use. After 96 h in culture, cells were stained 
for CD4 and analyzed by flow cytometry to assess CD4+ T cell proliferation by CFSE 
dilution. In the human suppression assay of T cell proliferation, CD4+ T cells were isolated 
by positive selection (Human CD4 Microbeads, Miltenyi; purity >95 %) from PBMCs of a 
control subject, labeled with CFSE (1 mM for 15 min at 37 °C in labeling buffer PBS/
0.1 %BSA), and co-cultured (50,000 cells/well) with CD33+HLA-DRneg MDSCs (Human 
CD33 MicroBeads, Miltenyi; purity >95 %) at a 2:1 ratio. T cell proliferation was induced 
by plate bound anti-CD3 (10 μg/ml) and anti-CD28 (10 μg/ml) antibodies. T cell 
proliferation in the absence or presence of MDSCs was examined by CFSE dilution by flow 
cytometry after 5 days of culture.
T cell differentiation in vitro
Spleens from 6- to 10-week-old miR-223−/− and WT mice were harvested and dissociated 
into a single cell suspension. After erythrocyte lysis, CD4+CD62L+ T cells were sorted 
using a FACS ARIA (BD Bioscience). Purified naive CD4+CD62L+ T cells from 
miR-223−/− and WT mice were cultured with antigen presenting cells (APC) and MOG35–55 
(20 μg/ml) as previously shown [19]. For standard Th1 differentiation, cells were cultured in 
the presence of IL-2 (10 ng/ml), IL-12 (20 ng/ml), and anti-IL-4 (10 μg/ml) (eBioscience). 
For standard Th17 differentiation, cells were cultured in the presence of IL-6 (20 ng/ml), 
TGF-β (3 ng/ml), IL-23 (10 ng/ml), anti-IL-4, and anti-IFN-γ (10 μg/ml) (eBioscience). 
After 5 days in culture, cells were collected for intracellular cytokine staining by FACS 
analysis.
Isolation of CNS inflammatory cells and MDSCs
Brain and spinal cord tissues from mice perfused with PBS were digested with collagenase 
IV (Sigma-Aldrich) for 30 min at 37 °C, resuspended in 37 % Percoll, and loaded between a 
30 and 70 % Percoll gradient. After centrifugation at 2000g for 20 min, CNS mononuclear 
cells were retrieved from the 37/70 % Percoll interface as previously done [38]. PMN- and 
MO-MDSC subsets were purified from CNS mononuclear cells by immunomagnetic 
separation using biotinylated anti-Ly6G and anti-Gr1 antibody and streptavidin-conjugated 
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MicroBeads as mentioned above (Miltenyi Biotec). Cell purity was >95 % by flow 
cytometric analysis using anti-CD11b and Gr-1 antibodies.
Quantitative real-time PCR
RNA was purified from murine tissues (spinal cord, brain, and lymphoid tissues) or human/
mouse sorted MDSCs (PMN and MO-MDSCs) using the RNeasy Micro Kit (Qiagen), 
converted into cDNA using the High-Capacity cDNA Reverse Transcription Kit or the 
MicroRNA Reverse Transcription Kit for microRNAs (Applied Biosystems), and used at 50 
ng/μl in quantitative real-time PCR (qRT-PCR) analysis (QuantStudio 3 Real-Time PCR 
System, Applied Biosystems). The ΔΔCt method was applied to determine differences in 
gene expression levels after normalization to the arithmetic mean of glyceralde-hyde 3-
phosphate dehydrogenase (GAPDH) for Arg1 and Stat3 or RNU48 and U6 as internal 
standards for miR-223 expression. The TaqMan probes (Life technologies) were the 
following: Arg1 (Mm00475988_m1; Hs00968979_m1); Stat3 (Mm01219775_m1; 
Hs1047580_m1); GAPDH (Mm99999915_g1; Hs99999905_m1); miR-223 (TM 
002295_mir); U6 (001973); and RNU48 (001006).
Western blot
The whole cell lysates from MO- and PMN-MDSCs were prepared as previously described 
[38], and total protein contents were measured using the Nanodrop (Thermo Scientific). 
Equal protein amounts (30 μg/lane) were loaded per lane for the MO- and PMN-MDSC 
samples. Protein was separated by electrophoresis on precast gel (Bio-Rad Laboratories), 
and transferred onto PVDF membranes (Millipore Corp.). The membranes were incubated 
overnight at 4 °C with rabbit anti-mouse monoclonal antibody targeting STAT3, anti-rabbit 
monoclonal antibody targeting pSTAT3, or an anti-rabbit anti-GAPDH (Cell Signaling) and 
then with the secondary anti-rabbit or anti-mouse antibodies HRP for 1 h. Signal was 
developed with a chemi-luminescent substrate (Thermo Fisher Scientific), and Kodak M35 
X-OMAT Automatic Processors was used for the detection of signals. Bands were 
quantitated in densitometry units after the processing with the ImageJ software (NIH).
3′ UTR luciferase reporter assays
The murine Stat3 3′ UTR was cloned into the psiCheck2 vector (Promega, Madison, WI) 
using PCR, and the control vector contained only GFP (empty). MiR-223 was cloned into 
the pMND vector [44]. Luciferase assays were performed using the Dual-Glo luciferase 
Assay (Promega) as described [44]. Renilla luciferase (experimental) was normalized to 
Firefly luciferase (transfection control) followed by the comparison of the Renilla/Firefly 
ratios of the control and Stat3 psiCheck2 sensor plasmids. MiR-223 was overexpressed via 
pMND in all conditions. 293T cells were co-transfected with the pMND-miR-223 over-
expression vector and a pSICheck2 control or Stat3 3′ UTR and assayed after 48 h.
Data analysis
Data were analyzed by t test or the equivalent non-parametric Mann–Whitney U test when 
comparing statistical differences between two groups. A one-way ANOVA or the equivalent 
non-parametric Kruskal–Wallis test with post hoc comparisons were used to analyze data 
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with more than two groups. EAE incidence data were analyzed by the Fisher exact test. P < 
0.05 was considered significant. Analyses were performed using GraphPad Prism 6.
Study approval
Human studies were approved by the Human Research Protection Office (HRPO) at 
Washington University in St. Louis (HRPO approval number: 201506145). For animal 
studies, all experimental procedures were approved by the animal studies committees of the 
Washington University School of Medicine (study approval number: 20150040).
Results
Peripheral blood MDSCs are reduced in RRMS patients
We examined the number of MDSCs in the peripheral blood of RRMS patients, including 
untreated (n = 24) and treated with GA (n = 10) subjects, as well as healthy control subjects 
(n = 16) by flow cytometry. MDSCs in humans are characterized by CD33+HLA-DRneg 
expression, with two different subsets defined based on surface marker expression. Human 
MO-MDSCs are defined as CD33+HLA-DR−CD14+CD15− and PMN-MDSCs as 
CD33+HLA-DR−CD14−CD15+ [26]. The gating strategy that was used to define MDSC 
subsets is illustrated in Fig. 1a on representative subjects from each group. We observed 
statistical significant lower numbers of total MDSCs in the whole blood of MS patients in 
comparison with healthy subjects (mean ± SD: 46 ± 41 vs. 172 ± 104 cells/μl, respectively; 
P < 0.0001 after post hoc comparison). Patients treated with GA had a modest increase in 
the numbers of total MDSCs (62 ± 37 cells/μl) compared to untreated patients, but this was 
not significantly different (Fig. 1b). Furthermore, the number of MO-MDSCs was 
significantly decreased in MS patients compared to healthy controls (mean ± SD: 19 ± 21 
vs. 60 ± 47 cells/μl, respectively; P = 0.0005), while GA treatment was associated with a 
slight increase compared to untreated patients (28 ± 26 cells/μl; Fig. 1c). Similar results 
were obtained when the percentages of MDSCs and MO-MDSCs of total blood leukocytes 
were considered instead of absolute numbers (Supplementary Fig. 1). No differences were 
observed into the PMN-MDSC subset, even though the number of this cell subset based on 
our gate strategy was very low (Fig. 1d). Importantly, total MDSCs isolated from the blood 
of a control subject were able to inhibit the proliferation of autologous T cells in vitro (Fig. 
1e). This functionally demonstrates the suppressive activity of MDSCs that we previously 
characterized by flow cytometry.
MiR-223 expression is higher in MDSCs isolated from MS patients compared to healthy 
controls
Next, we assessed miR-223 expression in MDSCs isolated from untreated RRMS patients (n 
= 11) and healthy controls (n = 10) by qPCR. We focused our attention on miR-223, because 
we have previously shown that its expression is altered in peripheral blood of MS compared 
to healthy subjects [42]. MDSCs were isolated from peripheral blood mononuclear cells 
(PBMCs) by sorting based on the expression of the CD33 and HLA-DR markers. MDSCs 
isolated from MS patients had statistically higher expression of miR-223 in comparison with 
MDSCs from control subjects (mean fold change ± SD over controls: 1.69 ± 0.35 vs. 0.78 
± 0.15, P = 0.02) (Fig. 1f). These results demonstrate that MS patients have lower numbers 
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of circulating suppressive MDSCs, in particular of the MO-MDSC subset and a 
dysregulation of MDSC miR-223 expression compared to healthy control subjects.
MiR-223 expression is upregulated in the spinal cord during clinical EAE
To gain more mechanistic insight into the potential role of miR-223 in MS, we utilized the 
EAE model. First, miR-223 expression was studied in spinal cord tissue isolated from naive 
and MOG35–55-immunized C57BL/6 mice at 5, 10, 15, and 30 day post-immunization (DPI; 
n = 4/group). MiR-223 expression was markedly increased in the spinal cord of immunized 
mice at the peak of disease (15 DPI) compared to naive mice (Fig. 2a, P = 0.02). While we 
did not find significant differences in miR-223 expression levels in the spleen, brain, and 
lymph nodes of naive and immunized mice at each time point, bone-marrow expression of 
miR-223 was lower from 10 to 30 DPI compared to baseline (Supplementary Fig. 2). The 
spinal cord is the major site of inflammation during EAE, and the observed increase of 
miR-223 expression during acute EAE could be related to inflammatory cell infiltration. 
Therefore, we analyzed miR-223 expression in mononuclear cells isolated from the spinal 
cord of mice with clinical EAE after sorting cell populations based on the expression of the 
CD11b and CD45 markers. MiR-223 was highly expressed in CD45dim−CD11b+ myeloid 
cells (macrophages and microglia), but was also detectable at lower levels in 
CD45highCD11b−cells which are mainly infiltrating lymphocytes (Fig. 2b).
MiR-223 deficient mice develop attenuated EAE compared to WT mice
To further clarify the role of miR-223 in CNS autoimmunity, EAE was induced in 
miR-223−/− and littermate wild-type (WT) controls by active immunization with MOG35–55. 
MiR-223−/− mice showed delayed disease onset, and a significantly less severe disease 
compared to control mice (Fig. 3a; Supplementary Table 2). Concordant with reduced 
clinical severity, histological analyses showed a decreased number of inflammatory 
infiltrates and demyelination (as revealed by solochrome cyanine and myelin basic protein 
staining) in the spinal cord of miR-223−/− mice compared to WT (Fig. 3b–e, h). Axonal 
damage detected by immunostaining for SMI32 revealed fewer SMI32-positive axons 
present in the miR-223−/− group compared to the control group (P = 0.04; Fig. 3f–h). In 
conclusion, active EAE is less severe clinically and pathologically in miR-223−/− compared 
to controls.
Lack of miR-223 interferes with priming of T cells against myelin peptides in periphery
Given the reduction in EAE severity in miR-223−/− mice compared to WT controls, we 
asked if a lack of miR-223 would interfere with the peripheral T cell priming phase and/or 
with the effector CNS phase during EAE. Therefore, adoptive transfer EAE was induced by 
transferring wild-type MOG-specific CD4+ T cells, polarized in vitro under Th1 conditions, 
into miR-223−/− and control mice. No differences in disease clinical course were noted in 
WT and miR-223−/− mice with passive transfer EAE (Fig. 4a), demonstrating no effects of 
miR223-deficiency on recipient mice injected with myelin-reactive WT T cells. This 
suggests that less severe active EAE in miR-223−/− mice is very likely related to the 
inhibition of T cell activation against the myelin antigen after immunization. Next, we 
explored the role of miR-223 in T cell priming during EAE. Control and miR-223−/− mice 
were immunized to induce EAE, and draining lymph nodes (DLNs) were isolated 6 DPI. 
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Lymph nodes draining the site of immunization in miR-223−/− mice were larger in size and 
had higher cellularity compared to WT mice (Supplementary Fig. 3a). Flow cytometric 
analyses of DLNs showed increased frequency of myeloid cells (CD11b+Gr1+ cells) in 
miR-223−/− mice relative to WT, with no differences in the number of T cells 
(Supplementary Fig. 3b–c). Intracellular production of IFN-γ, IL-17A, and GM-CSF, 
cytokines known to be relevant in EAE pathogenesis [41], was tested in CD4+ T cells from 
DLNs of miR-223−/− and WT mice on day 6 DPI (Fig. 4b). We observed significantly lower 
percentages of IFN-γ and GM-CSF producing CD4+ T cells along with a higher frequency 
of IL-17A-producing T cells, in DLNs from miR-223−/− mice relative to WT mice. In 
conclusion, the lack of miR-223 interferes with the induction phase of EAE and leads to 
altered cytokine production profiles by antigen-specific T cells.
Lack of mir-223 is not associated with an intrinsic T cell defect
Next, we studied the mechanisms leading to defective T cell priming in miR-223−/− mice 
after immunization with MOG35–55. MiR-223 is expressed at high levels in myeloid cells 
isolated from the CNS during EAE, but is also expressed by infiltrating lymphocytes (Fig. 
2b). Therefore, the altered cytokine production profile of miR-223-deficient T cells during 
EAE could be related to an intrinsic T cell defect due to the lack of miR-223. To test this 
hypothesis, we studied the abilities miR-223-deficient lymphocytes to differentiate into Th1 
and Th17 cells. Naive CD4+CD62+CD44− T cells were isolated from miR-223−/− and WT 
mice and cultured in vitro in Th1 and Th17 differentiating conditions using standard 
protocols [19]. Intracellular staining of cytokine production demonstrated that Th1 and Th17 
differentiation occurred normally in miR-223−/− CD4+ T cells (Fig. 4c, d). Taken together 
these data indicate that miR-223 does not function to regulate T cell encephalitogenicity, as 
miR-223−/− T cells do not show any intrinsic defect that could explain a defective activation 
in vivo against the myelin antigen during EAE. Our results suggest that the reduced T cell 
activation is a secondary event.
Lack of miR-223 is associated with the expansion of MO-MDSCs in the CNS during EAE
It is known that different subsets of immature myeloid cells with the capacity for the 
suppression of T cell activities accumulate in the spleen and CNS at EAE onset and peak 
[31, 48]. Specifically, PMN-MDSC and MO-MDSC numbers have been shown to 
progressively increase until the peak of EAE [18, 43]. In our study, we observed an 
expansion of the myeloid compartment in DLNs from miR-223−/− mice during EAE which 
could potentially affect T cell responses (Supplementary Fig. 3). First, we analyzed by flow 
cytometry absolute numbers of PMN-and MO-MDSCs in naïve WT and miR-223−/− 
lymphoid organs. In mice, these two subsets of MDSCs are defined based on the expression 
of Ly6C and Ly6G. No baseline differences in MDSC absolute numbers were detected in the 
spleen, bone marrow, or lymph nodes of naïve mice (Supplementary Fig. 4). Next, 
splenocytes and CNS mononuclear cells isolated from miR-223−/− and WT mice were 
characterized by flow cytometry during EAE. At the peak of the disease (15 DPI), absolute 
numbers of miR-223−/− PMN and MO-MDSCs were significantly higher in the spleen 
compared to WT counterparts (Fig. 5a, b). No differences were noted in the number of CD4+ 
T cells (Fig. 5b). Phenotypic characterization of CNS-isolated mononuclear cells from 
miR-223−/− and WT mice at EAE peak showed a significant increase of MO-MDSCs in 
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miR-223−/− compared to WT mice (Fig. 5c), but no differences in the number of (PMN)-
MDSCs between the two groups. Numbers of CNS-isolated CD4+ T cells were also similar 
in miR-223−/− and WT mice (Fig. 5c). We examined the expression of activation (CD40, 
CD86, and MHC-II) and inhibitory (PD-L1) markers on MO- and PMN-MDSCs isolated 
from the spleen and CNS at EAE peak by flow cytometry. We found reduced expression of 
activation markers and PD-L1 on miR-223−/− compared to WT MDSCs (Supplementary Fig. 
5a, b) [48]. The production of the pro-inflammatory cytokines TNF-α and GM-CSF was 
decreased, while IL-10 (anti-inflammatory cytokine) was increased in miR-223−/− PMN and 
MO-MDSCs compared to WT (Supplementary Fig. 5c). To characterize encephalitogenic T 
cell responses within the CNS during EAE, we analyzed by intracellular staining the 
cytokine production profile of CD4+ T cells isolated from the spinal cord of miR-223−/− and 
control mice with clinical disease. At the peak of the disease (15 DPI), CNS-infiltrating 
CD4+ T cells from miR-223−/− mice showed significant lower levels of IL-17A and GM-
CSF compared to WT mice, and a trend toward less IFN-γ production (Fig. 5d, e).
MiR-223 regulates MDSC suppressive functions
The observed expansion of MDSCs in miR-223−/− mice in peripheral lymphoid organs and 
in the CNS coinciding with lower production of the pathogenic cytokines IL-17A and GM-
CSF by CD4+ T cells after immunization with MOG35–55 suggests that miR-223 regulates 
the suppressive function in MDSCs. To evaluate the role of miR-223 in MDSC 
immunosuppressive functions, miR-223−/− and WT PMN- and MO-MDSCs were cultured 
in vitro at different ratios with 2D2 CD4+ T cells in the presence of MOG35–55. We 
measured 2D2 CD4+ T cell proliferation by CFSE dilution as well as cytokine production. 
MiR-223−/− MO-MDSCs had greater immunesuppressive effects on CD4+ T cell 
proliferation in comparison with WT MO-MDSCs, while no differences were noted for 
miR-223−/− and WT PMN-MDSCs (Fig. 6a). Similarly, miR-223−/− MO-MDSCs 
suppressed T cell production of IFN-γ, GM-CSF, and IL-17A more profoundly than WT 
MO-MDSCs (differences between the two groups were statistically significant for GM-CSF 
in all conditions, at the 1:8 ratio for IFN-γ, and for all other conditions, there was a 
consistent trend toward more suppression in miR-223−/− vs. WT MO-MDSCs) (Fig. 6b). 
Next, MO-MDSCs were isolated from the CNS of miR-223−/− and WT mice at EAE peak 
and cultured in vitro with 2D2 CD4+ T cells in the presence of MOG35–55. Consistent with 
what we observed previously, miR-223−/− MO-MDSCs obtained ex vivo from the inflamed 
CNS-suppressed MOG-specific proliferation more potently than WT MO-MDSCs (Fig. 6c). 
To study the role of miR-223 in modulating MDSC suppressive activity in vivo, miR-223−/− 
or WT MO-MDSCs were injected into EAE-immunized recipient C57BL/6 mice on day 5 
post-immunization. We observed the suppression of the clinical disease course in MDSC-
injected groups compared to the PBS-treated control group (Fig. 6d; P < 0.0001). However, 
mice that received miR-223−/− MDSCs showed the suppression of EAE that was persistent 
over time compared to those injected with WT MDSCs which ultimately developed maximal 
disease (Fig. 6d). CFSE labeling of MO-MDSCs before injection demonstrated their 
localization into the CNS during EAE (Fig. 6e). Furthermore, the analysis of cytokine 
production by CNS-isolated T cells during establish EAE (day 34 post-immunization) 
demonstrated the reduced production of the pro-inflammatory cytokines IL-17A, IFN-γ, and 
GM-CSF in miR-223−/− MDSCs compared to PBS-injected mice. No significant differences 
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were noted in T cell cytokine production between the WT MO-MDSC-treated mice and 
control PBS groups (consistent with similar clinical scores at time of analysis on >day 30 
post-immunization; Fig. 6f). All together, these data suggest that miR-223−/− MO-MDSCs 
are more efficient in suppressing CD4+ T cell proliferation and cytokine production in vitro 
and in vivo.
Regulation of MDSC immunosuppressive activity by miR-223 is associated with increased 
Arg1 and Stat3 expression
Immunosuppression by MDSCs involves multiple mechanisms, including depletion of L-
arginine via ARG1 and increased NO production by iNOS [49]. To evaluate how miR-223 
deficiency impacts on mechanisms of MDSC immunosuppression in our system, we 
examined Arg1 and iNOS transcript expressions by real-time PCR in bone-marrow-derived 
MO- and PMN- MDSCs from WT and miR-223−/− mice (Fig. 7a, b). Overall, Arg1 
expression was higher in MO-MDSCs compared to PMN-MDSCs in both genotypes. More 
importantly, the expression of Arg1 mRNA was significantly higher in MO-MDSCs isolated 
from miR-223−/− compared to WT mice (Fig. 7a). No difference in Arg1 expression was 
noted between WT and miR-223−/− PMN-MDSCs, and no differences were found in iNOS 
expression by WT and miR-223−/− MO- and PMN-MDSCs (data not shown). 
Immunofluorescence analysis by microscopy for ARG1 protein in miR-223−/− and WT MO-
MDSCs confirmed higher ARG1 expression at the protein level in MO-MDSCs lacking 
miR-223 compared to WT (Fig. 7b). Recent work using different mouse tumor models 
suggested that Arg1 expression is modulated by STAT3 [45]. Therefore, we examined the 
expression of Stat3 in bone-marrow-derived MO- and PMN-MDSCs from WT and 
miR-223−/− mice by real-time PCR. Stat3 expression was found to be significantly higher in 
miR-223−/− compared to WT MO-MDSCs (Fig. 7c). Western blot analysis of STAT3 and 
phosphorylated (p)STAT3 in MO- and PMN-MDSCs confirmed an increased expression of 
STAT3 in miR-223−/− vs. WT MO-MDSCs at the protein level, while no differences were 
noted in PMN-MDSCs (Fig. 7d). Furthermore, we found that the pSTAT3/STAT3 ratio was 
higher in miR-223−/− compared to WT MO-MDSCs, which supports the notion that the 
absence of miR-223 in MO-MDSCs is associated with increased levels of activated STAT3. 
All together, these results suggest that miR-223−/− MO-MDSCs have more potent 
suppressive activity compared to the WT counterpart, which was related to higher ARG1 
expression associated with increased STAT3 expression.
MiR-223 targets the Stat3 3′ UTR
Using the web-based target prediction software program “microRNA” (http://
www.microrna.org/microrna/home.do) to identify potential miR-223 targets, the 
transcription factor Stat3 was identified as a gene that could be negatively modulated by 
miR-223. Next, to determine whether Stat3 is a target of miR-223, we performed a 
luciferase assays using Stat3 3′ UTR. We found that miR-223 inhibited luciferase activity of 
a reporter containing Stat3 3′ UTR, but not that of an empty control reporter containing 
only GFP (Fig. 7e). Taken together, our data strongly link miR-223 to the STAT3-ARG1 
pathway.
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Decreased ARG1 and STAT3 in peripheral blood MDSCs form MS subjects compared to 
healthy controls
As reported above, RRMS patients display a significantly reduced number of total MDSCs 
and MO-MDSCs in peripheral blood compared to healthy controls and this was associated 
with an increased expression of miR-223 (Fig. 1a–f). To follow up on the increased 
expression of Arg1 and Stat3 in murine miR-223−/− MDCSs, we measured ARG1 and 
STAT3 expressions in human HLA-DR−CD33+ MDSCs sorted from peripheral blood of 
RRMS and age and gender-matched healthy control subjects (n = 8 and n = 10, 
respectively). Notably, the expression of ARG1 and STAT3 was significantly decreased in 
MDSCs from RRMS patients compared to healthy controls (mean fold change ± SD over 
controls for ARG1: 5.37 ± 5.9 vs. 1.22 ± 1.07, P = 0.03; STAT3: 0.77 ± 0.70 vs. 0.13 ± 0.13, 
P = 0.04) (Fig. 8a, b). These findings suggest that peripheral blood MDSCs in patients with 
RRMS are not only decreased in number, but might also be functionally impaired.
Discussion
In the present study, we demonstrate that RRMS patients display reduced numbers of 
circulating suppressive MDSCs compared to healthy control subjects, with a more 
pronounced reduction in the MO-MDSC subset. Importantly, the expression of miR-223 was 
significantly increased in MDSCs from MS patients compared to healthy controls and this 
was associated with decreased expression of ARG1 and of the transcription factor STAT3. In 
parallel mouse studies, miR-223 deficiency led to reduced EAE severity and pathology 
which was associated with an increase in MDSC number in the spleen and CNS. Murine 
MO-MDSCs lacking miR-223 demonstrated increased suppressive function on T cell 
proliferation and cytokine production, with increased expression of Stat3 and Arg1 in mouse 
T cells. Furthermore, we provide evidence that Stat3 is a miR-223 target gene.
Although MS autoimmunity is thought to be primarily driven by T cells, myeloid-derived 
cells are the most abundant cells associated with CNS demyelinating lesions in MS [32]. 
Myeloid cells critically shape adaptive immune responses and the inflammatory environment 
during CNS autoimmunity [32]. MDSCs are a heterogeneous group of undifferentiated 
myeloid cells present in the bone marrow that during an inflammatory event can expand, 
circulate in the blood, and acquire ability to suppress T cell functions [32]. Immune-
suppressive capability of MDSCs was described first in tumor-bearing mice [27], but 
MDSCs can also participate to the pathological processes of autoimmune diseases [32]. 
Published studies describe a role for MDSCs in the regulation of the immune responses 
during EAE [18, 31, 43, 48, 49]. Increased numbers of MO and PMN–MDSCs were 
reported in the spleen and blood in mice with EAE, and these cells were shown to gain 
access to the inflamed CNS [25, 31, 49]. Other investigators have shown that adoptive 
transfer of MO or PMN-MDSCs to mice primed to develop EAE ameliorated the clinical 
course and delayed disease onset. Improved clinical EAE was associated with decreased 
demyelination and inhibition of T cell responses with increased T cell apoptosis [18, 31].
Up to now, the role of MDSCs in MS has been poorly characterized. Here, we report that 
RRMS patients display significantly reduced numbers of circulating total MDSCs, with the 
main reduction in MO-MDSCs, compared to healthy controls. Treatment with GA 
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moderately increased the number of MDSCs in peripheral blood, compared to untreated MS 
patients. Also noted was a trend toward lower numbers of PMN-MDSCs in MS. To our 
knowledge, ours is the first report that studied total MDSCs and MO-MDSCs in MS 
patients. Previous work by another group reported an enrichment of circulating PMN-
MDSCs in MS patients with active disease, while no changes in their numbers were noted in 
RRMS patients during remission compared to healthy controls [18]. Different reasons could 
explain this discrepancy in regard of circulating PMN-MDSC frequencies in RRMS and 
healthy controls between this previous work and ours. These would include genetic 
differences in the cohorts studied, exposure to disease-modifying therapies, and/or possible 
differences in the isolation procedure or gating strategies for MDSCs. Herein, we have also 
demonstrated human MDSC suppressive activity on T cell proliferation in vitro. The 
analysis of the suppressive potential of peripheral blood MDSCs isolated from MS vs. 
healthy control subjects is an important future study to be done.
Decreased numbers of MDSCs and MO-MDSCs were associated with increased MDSC 
expression of miR-223 in MS patients compared to heathy controls. This is an important and 
novel finding suggesting the possible role of miR-223 in modulating MDSC biology in the 
context of autoimmunity. Dysregulation of several miRNAs has been observed in the blood 
and CNS tissues of MS compared to control subjects by microarray profiling [9, 42]. 
MiR-223 was found to be upregulated by microarray analysis in the whole blood [22] and in 
active brain lesions in MS patients compared to control subjects. A recent study showed the 
upregulation of miR-223 also in normal appearing white matter in MS patients [15]. 
MiR-223 modulates myeloid cell differentiation and number [8]. Specifically, it was shown 
to act as a negative regulator of granulocytic differentiation and activation in neutrophils [20] 
which leads to increased numbers of granulocyte/myeloid progenitors in the bone marrow of 
miR-223−/− mice [7, 20].
Our study shows that miR-223 expression is upregulated in the spinal cord of C57BL/6 mice 
with active EAE and it is highly expressed in myeloid cells isolated from the inflamed CNS. 
Furthermore, active EAE was attenuated clinically, histopathologically and with reduced 
frequencies of IFN-γ+, IL-17A+, and GM-CSF+ CNS-infiltrating CD4+ T cells in miR-223-
deficient mice compared to littermate control mice. In contrast, when adoptive transfer EAE 
was induced by injecting encephalitogenic Th1 cells into WT and miR-223−/− recipient 
mice, we did not observe differences in the EAE clinical course between the two genotypes. 
In the setting of passive EAE, we analyzed MDSC accumulation in the spleen or CNS (day 
15 post-transfer) and we did not observe differences between WT and miR-223−/− recipient 
mice in MDSC numbers as well as their suppressive function on T cell cytokine production 
(data not shown). This suggests that once WT T cells are primed against MOG35–55, lack of 
miR-223 does not interfere with subsequent effector events, including lymphocyte migration 
though the blood brain barrier, and re-activation in the CNS and subsequent CNS tissue 
damage. Therefore, we surmise that the effect of miR-223 deficiency on active EAE is very 
likely dependent on events leading to the generation of MDSCs during the peripheral phase 
of antigen-specific T cell activation. These suppressive cells could in turn express their 
modulatory potential on T cell functions either in the periphery and/or within the CNS, 
where they also accumulate during clinical disease. At 6 DPI, we observed increased 
accumulation of MDSCs in lymph nodes draining the site of immunization with 
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significantly higher numbers of CD4+ T cells producing IL-17A in miR-223−/− compared to 
WT mice. This latter result was surprising given the well-known pathogenic role of IL-17A 
in EAE and difficult to reconcile with the fact that active EAE is attenuated in miR-223−/− 
mice. However, at EAE peak in the CNS, we observed a reduced number of Th17 cells in 
miR-223−/− compared to WT mice, which is in agreement with the observed reduced disease 
severity. Therefore, the higher numbers of IL-17A cells found in DLN in miR-223−/− did not 
result in increased CNS pathology, which could be explained by several different scenarios. 
The expansion of MDSCs in DLN at time of T cell priming in miR-223−/− mice could 
promote Th17 polarization as previously suggested in EAE [46] and be responsible for the 
higher numbers IL-17A producing T cells detected in DLNs before EAE onset in miR-223-
deficient mice compared to WT. On the other end, MDSCs and T cells can reciprocally 
influence each other [33, 49]. In fact, IL-17A+CD4+ T cells can increase the suppressive 
activity of MDSCs through Arg1 upregulation [34]. MDSCs with enhanced suppressive 
activity might in turn lead to lower numbers of Th17 cells at later stages of EAE. Another 
possible scenario to explain the reduced clinical course despite increased numbers of Th17 
cells generated in DLNs in miR-223−/− mice could be that the increased MDSC numbers led 
to the conversion of the Th17 cells into regulatory T cells (Tregs) [16], a subset of T cells 
capable of suppressing EAE [38]. Recently, it has been shown that Th17 cells can convert 
into Tregs [47]. Perhaps, this process is part of the mechanism of action of MDSCs in 
suppressing T cell functions [33]. In support of this hypothesis, we have preliminary results 
showing an increased number of CNS-infiltrating CD4+CD25+Foxp3+ T regs in the CNS 
during clinical EAE in miR-223−/− compared to WT mice (data not shown). The attenuation 
of active EAE in miR-223−/− mice was recently reported by another group [17]. Consistent 
with our results, they also found defective T cell priming when miR-223 is lacking and 
attributed this observation to a deficiency in T cell activation by myeloid dendritic cells 
(DCs). In contrast, our results suggest that miR-223 deficiency leads to defective T cell 
functions due to an expansion of MDSCs with enhanced suppressive activities.
Herein, we provide mechanistic information on the molecular pathways regulated by 
miR-223 in MDSCs. Furthermore, we provide evidence that Stat3 is a miR-223 target gene 
and lack of miR-223 in murine MDSCs is indeed associated with increased expression of 
Stat3 compared to WT cells. STAT3 plays important roles in the expansion and activities of 
MDSCs, as shown in several tumor models [5, 27]. Here, we speculate that miR-223 could 
also modulate MDSC accumulation in STAT3-mediated mechanisms in the setting of EAE 
and Arg1, a downstream STAT3 target gene and a potent T cell inhibitor [45]. In agreement 
with this notion, higher Stat3 expression in miR-223−/− murine MDSCs was associated with 
increased expression of Arg1 compared to the WT counterpart. This suggests that the hyper-
activation of the STAT3-ARG1 pathway might be responsible for more potent 
immunosuppression by miR-223−/− compared to WT MDSCs. Taken together, these findings 
support the notion that miR-223 is a critical regulator of Arg1 and Stat3 genes which would 
impact on MDSC suppressive functions. Importantly, in this study, MDSCs isolated from 
RRMS had higher expression of miR-223 compared to those in healthy control subjects. 
This was associated with a decreased expression of STAT3 and ARG1. This inversely 
recapitulates what we have observed in the murine system and leads to the hypothesis that 
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circulating MDSCs in RRMS are not only defective in number, but also in 
immunosuppressive capacity.
In conclusion, our study reports for the first time that the numbers of total circulating 
MDSCs and MO-MDSCs are reduced in RRMS patients compared to healthy controls and 
this was associated with higher MDSC expression of miR-223. Through validation in the 
murine MS model, we underscore the critical role of mir-223 in modulating MDSC numbers 
and suppressive activities, possibly through effects on STAT3 and Arg1 pathways. 
Understanding the specific molecular events that regulate MDSC number and function could 
lead to the design of new strategies of immune intervention in MS.
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Fig. 1. 
Reduced number of peripheral blood MDSCs with higher miR-223 expression in relapsing-
remitting MS patients compared to healthy controls. a Representative flow cytometric plots 
for MDSCs (upper panel) and MO-MDSCs (lower panel) in the whole blood of one RRMS 
patient and one healthy control individual. In both upper and lower panels, cells were gated 
on live cells based on FSC/SSC characteristics and singlet cells. Next, in the upper panel 
MDSCs were gated as CD33+ HLA-DR−. In the lower panel, HLADR−cells were displayed 
for CD14 and CD33 expression to identify the MO-MDSC subset defined as CD14+ CD33+ 
(all these cells are also CD15−). Percentages refer to gated cells. b–d Total numbers (cells/
μl) of MDSCs, MO- and PMN-MDSCs in the whole blood of untreated RRMS patients (n = 
24), GA patients (n = 10), and in healthy individuals (n = 16). MDSCs are defined as 
HLADR−CD33+; MO-MDSCs as HLA-DR−CD33+CD15−CD14+, and PMN-MDSCs as 
HLA-DR−CD33+CD15+CD14−. e Suppression of T cell proliferation assay. MDSCs were 
isolated from the blood of a control subject and co-cultured for 5 days with autologous 
CFSE-labeled CD4+ T cells (1:2 ratio) in the presence of anti-CD3 and anti-CD28. T cell 
proliferation in the absence or presence of MDSCs was examined by CSFE dilution by flow 
cytometry. f Scatter plot of the distribution of miR-223 expression levels in MDSCs from 
RRMS patients (n = 11) and healthy controls (n = 10). Red squares in the scatter plots in b–
d and in f represent RRMS patients having a relapse. Error bars are mean ± SD. P values 
were calculated by Mann–Whiteny U test or Kruskal–Wallis tests with post hoc comparisons 
if more than two groups
Cantoni et al. Page 20
Acta Neuropathol. Author manuscript; available in PMC 2017 May 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 2. 
MiR-223 is expressed in myeloid cells in the spinal cord at the peak of EAE. a MiR-223 
expression in the spinal cord taken from naïve mice and on days 5, 10 15, and 30 post-EAE 
immunization (n = 4 mice/time point) analyzed by quantitative RT-PCR (qRT-PCR). U6 
snRNA was used as endogenous controls. b MiR-223 expression in CD45+CD11b− 
(lymphocytes) and CD45+CD11b+ (myeloid cell) populations sorted from infiltrating 
mononuclear cells in the spinal cord on day 15 post-immunization (peak of disease) and 
analyzed by qRT-PCR. miR-223 expression is shown as relative to miR-223 expression in 
myeloid and T cells isolated from naïve splenocytes. Error bars represent mean ± SEM. P 
values were calculated by Kruskal–Wallis H test
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Fig. 3. 
Lack of miR-223 ameliorates EAE. a Active EAE was induced in miR-223−/− (n = 8) and 
WT mice (n = 5) with MOG35–55. MiR-223−/− displayed delayed and significantly less 
clinical EAE than WT mice (P < 0.0001 by two-way ANOVA). One representative 
experiment out of four performed is shown. Data are shown as mean clinical score ± SEM. 
b–e Inflammation and demyelination were assessed using H&E and solochrome cyanine 
staining of spinal cord sections from immunized WT (n = 5) (b, d) and miR-223−/− (c, e) 
mice (n = 5) at disease peak. MiR-223−/− mice showed less inflammatory cells (black 
arrows) infiltrating the parenchyma compared to WT mice. f, g Spinal cord sections from 
EAE affected WT and miR-223−/− mice were stained for myelin basic protein (in green) and 
SMI32 (in red), to detect myelin and damaged axons, respectively. 10× magnification. Scale 
bars 100 μm (b–g). h Quantification of inflammation, demyelination, and axonal damage. 
Data are shown as mean ± SEM (5 mice/group) from one experiment representative of three 
performed. Statistical significance determined by Mann–Whitney U test
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Fig. 4. 
Defective T cell priming in miR-223−/− mice is not due to an intrinsic T cell defect. a 
Clinical course of adoptively transferred EAE induced by the injection of activated 
MOG35–55-specific CD4+ T cells obtained from C57BL/6 mice into miR-223−/− or WT 
recipients (n = 5 mice/group). Data are mean clinical score ± SEM of all animals in each 
group. Data are representative from three experiments performed with similar results. b 
Scatter plot of the percentages of IFN-γ, IL-17A, and GM-CSF in draining lymph nodes 
CD4+ T cells of WT and miR-223−/− mice at day 6 post-immunization (n = 5 mice/group). 
Numbers indicate the percentage of cytokine-producing CD4+ T cells. Data are 
representative of three independent experiments. Error bars are mean ± SEM. c, d WT and 
miR-223−/−-derived naive CD4+ T cells cultured in vitro under Th1 or Th17 conditions were 
restimulated with PMA/ionomycin on day 5 to analyze IL-17A and IFN-γ intracellular 
production by flow cytometry. In d, numbers represent frequencies of IFN-γ- and IL-17A-
producing CD4+ T cells. Data are representative of three independent experiments. Error 
bars are mean ± SEM. P values were calculated by Mann–Whitney U test
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Fig. 5. 
Expansion of MDSCs in the spleen and in the CNS of miR-223−/− mice during EAE. a–c 
Splenocytes and CNS-infiltrating cells from immunized WT and miR-223−/− mice on day 15 
post-immunization (EAE peak) analyzed by flow cytometry. a Representative flow 
cytometric analysis of frequencies of MO and PMN-MDSC populations from the spleen 
(top) and CNS (bottom) for the indicated groups. The gating strategy first included 
Zombie−CD45+CD11b+. Next, MO-MDSCs were defined as CD11b+Ly6Chigh cells and 
PMN-MDSCs as CD11b+Gr1+. Quantification of the absolute numbers of MO or PMN-
MDSCs and CD4+ T cells was calculated from the percentages based on the total number of 
b splenocytes or c CNS-infiltrating cells isolated/mouse. d Representative plots of 
intracellular staining of CNS-infiltrating CD4+ T cells for the indicated cytokines. e 
Intracellular production of IFN-γ, IL-17A, and GM-CSF by CNS-derived CD4+ T cells 
from WT and miR-223−/− mice with EAE analyzed by flow cytometry. Numbers indicate 
percentage of CD4+ cells. These results are from one representative experiment of three 
performed. P values were calculated by Mann–Whitney U test
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Fig. 6. 
MiR-223−/− MO-MDSCs are more potent immuno-suppressors compared to WT in vitro 
and in vivo. a Proliferation and b cytokine production of PMN or MO-MDSCs isolated from 
the bone marrow of WT and miR-223−/− mice and co-cultured with CFSE-labeled CD4+ T 
cells from 2D2 transgenic mice (1:2, 1:4, and 1:8 ratios) in the presence of MOG35–55. Error 
bars are mean ± SEM. c Proliferation of MO-MDSCs isolated from the CNS of EAE WT 
and miR-223−/− mice and co-cultured with CFSE-labeled CD4+ T cells from 2D2 transgenic 
mice (1:1, 1:2, 1:4, 1:8, and 1:16 ratios) in the presence of MOG35–55. A representative 
experiment from a total of four is showed. P values were calculated by Mann–Whitney U 
test. d Clinical course of active EAE in C57BL/6 mice immunized with MOG35-55 and 
injected (day 5 post-immunization) with WT or miR-223−/− MO-MDSCs. Control group 
was injected with PBS (P < 0.0001 by two-way ANOVA; the graph refers to one experiment 
of a total of two performed with similar results). e. WT and miR-223−/− MO-MDSCs were 
labeled with CFSE before injection into EAE-immunized mice and then detected by flow 
cytometric analysis in CNS-infiltrating mononuclear cells during ongoing EAE. The PBS 
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control group was CFSE negative. f Cytokine production by CNS-isolated T cells during 
establish EAE (>day 30 post-immunization) in PBS-, WT-, or miR-223−/− MDSC-injected 
groups (P ≤ 0.05 by Kruskal–Wallis H test)
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Fig. 7. 
MiR-223−/− regulates Arg1 and targets Stat3. a qRT-PCR analysis of arginase 1 (Arg1) in 
PMN and MO-MDSCs isolated from WT and miR-223−/− mice (n = 3 mice/group). GAPDH 
probe was used as endogenous control. Error bars are mean ± SEM. A representative 
experiment from a total of four is showed. P values were calculated by Mann–Whitney U 
test. b Immunofluorescence staining by microscopy for ARG1 (in red) and Gr1 (in green) in 
BM-derived MO-MDSCs from WT and miR-223−/− mice. 60× magnification. Scale bars 25 
μm. Quantification of immunofluorescence analyses as percentages of ARG1+ Gr1+ MO-
MDSCs of total Gr1+ MO-MDSCs from WT and miR-223−/− mice counted/field. c qRT-
PCR analysis of STAT3 expression in PMN and MO-MDSCs isolated from WT and 
miR-223−/− mice (n = 3 mice/group). GAPDH probe was used as endogenous control. d 
Western blot analysis of STAT3 and pSTAT3 expression levels in MO- and PMN-MDSCs 
derived from the bone marrow of WT and miR-223−/− mice. STAT3 levels were normalized 
on GAPDH, while pSTAT3 was normalized on STAT3. e Luciferase assays showing that 
miR-223 downregulates the expression of Stat3 by targeting its 3′UTR. MiR-223 was 
overexpressed via pMND in all conditions. 293T cells were co-transfected with the pMND-
miR-223 over-expression vector and a pSICheck2 control or Stat3 3′ UTR and assayed after 
48 h (N = 3 independent experiments, with n = 9 biological replicates, P < 0.0001 by paired 
t test)
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Fig. 8. 
Lower ARG1 and STAT3 expressions in relapsing-remitting MS patients compared to 
healthy controls. a, b Scatter plot of the distribution of STAT3 and ARG1 levels in 
circulating MDSCs from RRMS patients (n = 8) and healthy controls (n = 10), respectively. 
Error bars represent the mean ± SD. P values were calculated by Mann–Whitney U test
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